AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23794338
Drug: Azithromycin, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, amoxicillin, and omeprazole
Trial: 23794338
Drug: Clarithromycin, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Trial: 23794338
Drug: Azithromycin, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Trial: 21784839
Drug: ARB (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (100 mg/d losartan)
Trial: 21784839
Drug: ARB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide)
Trial: 10954001
Drug: Aspirin D,L-lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin D,L-lysine (18 mg/kg)
Trial: 8243524
Drug: Pentaglobin (IgM-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaglobin (IgM-enriched intravenous immunoglobulin)
Trial: 30095659
Drug: Prophylactic infusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusion of phenylephrine
Trial: 27751846
Drug: Regorafenib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (160 mg per day, 3 weeks on and 1 week off)
Trial: 22397215
Drug: Sodium enoxaparin
RxNorm normalized name: Enoxaparin Sodium
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium enoxaparin treatment for 10 days, followed by an additional 10 days after a 10-day no treatment period.
Trial: 20546462
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus oral iron (single intravenous iron polymaltose infusion + daily oral ferrous sulphate 250 mg)
Trial: 20546462
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron only (daily oral ferrous sulphate 250 mg)
Trial: 20546462
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus oral iron
Trial: 20546462
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron only
Trial: 18192624
Drug: After-school treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After-school treatment program (10-week duration)
Trial: 11759825
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg/day
Trial: 11759825
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg/every other day
Trial: 7827298
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation
Trial: 2962597
Drug: CT with
RxNorm normalized name: Impact with Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT with intravenous contrast enhancement
Trial: 31707860
Drug: SNF472 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNF472 300 mg
Trial: 31707860
Drug: SNF472 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNF472 600 mg
Trial: 24824633
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg three times a day
Trial: 23328996
Drug: Docetaxel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (30 mg/m²) and cisplatin (30 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Trial: 23328996
Drug: Single-agent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent cisplatin (40 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Trial: 8630937
Drug: 5‐FU infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU infusions plus oral HCFU administration (Group A)
Trial: 8630937
Drug: 5‐FU injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU injections (Group B)
Trial: 1558344
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (325 mg aspirin, 75 mg dipyridamole, starting 12 hours preoperatively and continuing for 1 year)
Trial: 1558344
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication identical in appearance to the study drugs
Trial: 2859043
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg propranolol LA
Trial: 29855153
Drug: Dexamethasone (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.7 mg implant)
Trial: 22698597
Drug: Tricuspid regurgitation
RxNorm normalized name: Maclura tricuspidata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricuspid regurgitation treatment (group T)
Trial: 22698597
Drug: No tricuspid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tricuspid regurgitation treatment (group no-T)
Trial: 22698597
Drug: Tricuspid regurgitation
RxNorm normalized name: Maclura tricuspidata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricuspid regurgitation treatment (group T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Trial: 22698597
Drug: No tricuspid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tricuspid regurgitation treatment (group no-T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Trial: 22698597
Drug: No tricuspid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tricuspid regurgitation treatment (group no-T) in subgroup B (TAD/BSA > 21 mm/m2)
Trial: 2325569
Drug: Rocaltrol 0.25
RxNorm normalized name: Rocaltrol 0.25mcg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocaltrol 0.25 micrograms twice daily
Trial: 23824103
Drug: Salvage pulsed-dose-rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage pulsed-dose-rate brachytherapy (PDR-BT)
Trial: 17335364
Drug: Full-mouth scaling
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth scaling and root planing (SRP) with azithromycin administered orally 3 days before SRP
Trial: 11164856
Drug: Gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1200 mg/day for 30 days
Trial: 9182112
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg bid
Trial: 9182112
Drug: Amoxycillin/clavulanate 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate 500 mg/125 mg tid
Trial: 20926948
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg/day with standard conventional therapy (n=55)
Trial: 20926948
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=55)
Trial: 16083709
Drug: Peginterferon-alpha-2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 16 weeks (group A)
Trial: 16083709
Drug: Peginterferon-alpha-2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group B)
Trial: 16083709
Drug: Peginterferon-alpha-2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group C)
Trial: 16083709
Drug: HCV-3 patients
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV-3 patients with high viral load (>800,000 IU/mL)
Trial: 16083709
Drug: HCV-3 patients
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV-3 patients with low viral load (≤800,000 IU/mL)
Trial: 10601131
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 to 40 mg/d)
Trial: 8543490
Drug: iv meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv meropenem (1 g every 8 h)
Trial: 8543490
Drug: iv ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv ceftazidime (2 g every 8 h) plus iv amikacin (15 mg/kg/day in two or three divided doses)
Trial: 2024812
Drug: Colchicine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.6 mg three times per day)
Trial: 29523194
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution umbilical cord cleansing regimen
Trial: 22564993
Drug: metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 850 mg/twice per day
Trial: 16568708
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with Der p 1 standardized allergens (total dose of 10,469 UBE)
Trial: 16568708
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with Der p 1 standardized allergens
Trial: 7760242
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 10.0 g/kg/d of dextrose and 4.0 g/kg/d of fat
Trial: 7760242
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 19.0 g/kg/d of dextrose and 0.5 g/kg/d of fat
Trial: 26022762
Drug: BMSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMSC therapy
Trial: 24590053
Drug: White light/240‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White light/240‐mg caffeine (CAF)
Trial: 24590053
Drug: Blue light/240‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light/240‐mg caffeine (BCAF)
Trial: 22594651
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine content (VLNC) cigarettes plus usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support)
Trial: 12850610
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg per day
Trial: 12850610
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg per day
Trial: 10462244
Drug: Meningococcal A/C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal A/C polysaccharide vaccine (MPS)
Trial: 8857079
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 12 mmol magnesium
Trial: 8857079
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 24 mmol magnesium
Trial: 8857079
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 4 mmol magnesium
Trial: 8857079
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 8 mmol magnesium
Trial: 31910279
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and zinc supplementation (5 mg of folic acid and 30 mg of elemental zinc daily for 6 months)
Trial: 23295056
Drug: Entecavir monotherapy
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir monotherapy
Trial: 18682741
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole)
Trial: 9391254
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide (50 pg/h for 48 hours)
Trial: 7944837
Drug: Glycosylated hemoglobin
RxNorm normalized name: Glycosylated hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group taking insulin)
Trial: 7944837
Drug: Glycosylated hemoglobin
RxNorm normalized name: Glycosylated hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group not taking insulin)
Trial: 28643427
Drug: PVR after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVR after uroflowmetry in patients with bladder capacity >400 mL
Trial: 28643427
Drug: Random PVR
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random PVR in patients with bladder capacity >400 mL
Trial: 24066743
Drug: CMX001 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX001 (100 mg twice weekly)
Trial: 24066743
Drug: CMX001 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX001 (200 mg weekly or higher)
Trial: 24066743
Drug: CMX001 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX001 (200 mg twice weekly)
Trial: 12705362
Drug: L-thyroxine 8-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine 8-10 microg/kg/day in newborns
Trial: 12705362
Drug: L-thyroxine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine 15 microg/kg/day in infants
Trial: 3522407
Drug: Tinidazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (single oral 2 g dose)
Trial: 11229858
Drug: Antipyretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyretic treatment
Trial: 8281625
Drug: Droloxifene 200
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 200 mg
Trial: 8281625
Drug: Droloxifene 300
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 300 mg
Trial: 2912024
Drug: vindesine 3
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vindesine 3 mg/m2 weekly
Trial: 2912024
Drug: spirogermanium 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spirogermanium 80 mg/m2 three times weekly (escalated to 120 mg/m2)
Trial: 1155056
Drug: Ampicillin plus
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin plus nasal decongestant
Trial: 1155056
Drug: Cephradine plus
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephradine plus nasal decongestant
Trial: 1155056
Drug: Erythromycinestolate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycinestolate plus nasal decongestant
Trial: 28768173
Drug: NNC0090-2746 (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0090-2746 (1.8 mg subcutaneously once daily)
Trial: 28768173
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg subcutaneously once daily)
Trial: 24254035
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acupressure treatment)
Trial: 19997797
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefmetazol on the day of surgery (group 1)
Trial: 19997797
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefotiam for 3 days (group 2)
Trial: 22524979
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (OFIRMEV(®); 1,000 mg, 15 minute infusion)
Trial: 22524979
Drug: PO acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO acetaminophen (2 Tylenol(®) 500 mg caplets)
Trial: 22524979
Drug: PR acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR acetaminophen (2 Feverall(®) 650 mg suppositories)
Trial: 12842371
Drug: Standard measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard measles vaccine (control)
Trial: 10471182
Drug: Vaxigrip injection
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxigrip injection
Trial: 2190758
Drug: Hydrocolloid dermatologic
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dermatologic patch (Actiderm) plus topical beta‐methasone valerate 0.1 percent cream
Trial: 2190758
Drug: Topical beta‐methasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beta‐methasone valerate 0.1 percent cream alone
Trial: 2190758
Drug: Hydrocolloid dermatologic
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dermatologic patch (Actiderm) alone
Trial: 27252754
Drug: Fifth generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifth generation bonding agent
Trial: 27252754
Drug: Seventh generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seventh generation bonding agent
Trial: 23945138
Drug: WalkLink+: prompted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WalkLink+: prompted and provided feedback on participants' online and in‐person social‐network interactions to expand networks for PA, plus provided evidence‐based online walking program and weekly walking tips
Trial: 23945138
Drug: WalkLink: evidence‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WalkLink: evidence‐based online walking program and weekly tips only
Trial: 23945138
Drug: Minimal Treatment
RxNorm normalized name: Minimally modified low density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Treatment Control: weekly tips only
Trial: 20584793
Drug: Injection plus
RxNorm normalized name: Bimectin Plus Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection plus exercise
Trial: 10971105
Drug: 0.5 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 IU/kg per week subcutaneous recombinant human GH
Trial: 10971105
Drug: 1.0 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 IU/kg per week subcutaneous recombinant human GH
Trial: 10971105
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of GH
Trial: 8569467
Drug: Prednisone (CS)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (CS) + oral cyclophosphamide (CYC) + plasma exchanges (PE)
Trial: 8569467
Drug: CS +
RxNorm normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS + oral CY
Trial: 31952938
Drug: Probiotics (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (5 × 10^9 cfu/capsule)
Trial: 27214145
Drug: Inhaled, nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, nebulized AZD5423 at doses of at least 300 μg for 2 weeks
Trial: 27214145
Drug: Inhaled, nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, nebulized AZD5423
Trial: 24862742
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral MPH
Trial: 10658377
Drug: Optimal protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal protamine dose determined for residual heparin concentration (P group)
Trial: 10658377
Drug: Initial fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial fixed dose of protamine, 1.67 mg protamine per milligram total heparin (C group)
Trial: 8557059
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg salbutamol
Trial: 2095163
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 ml of 2% glucose solution)
Trial: 6985882
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of UDCA
Trial: 6985882
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day of UDCA
Trial: 31899739
Drug: Osteoblastic cell
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoblastic cell therapy
Trial: 31899739
Drug: BMAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC treatment
Trial: 31158840
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl 20 mg
Trial: 31158840
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl 80 mg